January 10, 2018
The US FDA has granted Breakthrough Therapy designation for a combination therapy pairing Eisai’s multi-kinase inhibitor Lenvima (lenvatinib) and US Merck’s PD-1 inhibitor Keytruda (pembrolizumab) for the treatment of advanced/metastatic renal cell carcinoma (RCC), the two companies said on January...read more